参附注射液治疗急性心肌梗死合并心源性休克的系统评价与Meta分析  

The System Evaluation and Meta Analysis of Shenfu Injection on Acute Myocardial Infarction Complicated with Cardiac Shock

作　　者：张春漪 逯阳 张良登[3,4] 

机构地区：[1]北京密云县中医医院,北京101500 [2]北京国医药研究院,北京100050 [3]北京中医药大学东直门医院,北京100700 [4]中国中医科学院望京医院,北京100102

出　　处：《中国中医急症》2015年第11期1915-1917,1928,共4页Journal of Emergency in Traditional Chinese Medicine

基　　金：首都医学发展科研基金北京医学卫生科技联合攻关项目(SF2007I04)

摘　　要：目的评价参附注射液治疗急性心肌梗死(AMI)合并心源性休克(CS)的安全性与有效性。方法通过检索10个外文、中文数据库,纳入参附注射液治疗AMI合并CS随机对照试验(RCT)文献,定量、定性合成分析RCT终点结局与方法学质量。结果共有8个RCT总计446例AMI合并CS患者,全部RCT试验组采用参附注射液结合西药及常规措施救治,对照组采用西药及常规措施救治,有3个RCT报道主要终点死亡事件。对次要终点结局行Meta分析表明试验组治疗后总有效率、心率改善效果优于对照组。系统评价方法学质量表明纳入RCT均属于高偏倚风险级别。结论参附注射液治疗AMI合并CS安全有效,然而因为RCT方法学质量偏低,建议开展更为严格的RCT以获取充分证据支持临床应用参附注射液治疗AMI合并CS。Objective： To evaluate the safety and effectiveness of Shenfu Injection on acute myocardial infarction complicated with cardiac shock. Methods： Literature on Shenfu Injection in the treatment of AMI combined with CS randomized controlled trial was chosen by searching 10 foreign and Chinese database. The end result of RCT and the quality of Methods were analyzed quantitatively and qualitatively. Results： There were 8 RCT,including446 cases with AMI combined with CS,receiving Shenfu injection combined with the treatment of Western medicine and conventional measures,and there were 3 RCT reporting the primary end point of death events. Meta analysis of secondary outcome showed that the total effective rate and heart rate of the experimental group were better than those in the control group. The quality of the Methods study showed that the inclusion of RCT was a high risk of bias. Conclusion： Shenfu Injection on AMI combined with CS is safe and effective. However,because of the low quality of RCT Methods,it is recommended to carry out more stringent RCT to obtain sufficient evidence to support the clinical application of Shenfu Injection on AMI combined with CS.

关 键 词：参附注射液 急性心肌梗死合并心源性休克 Meta分析与系统评价 中西医结合 

分 类 号：R542.22[医药卫生—心血管疾病]